Biomarker Use in Colorectal Cancer Therapy

被引：29

作者：

Kelley, Robin K. ^{[1
]}

Wang, Grace ^{[2
]}

Venook, Alan P.

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Med, San Francisco, CA 94115 USA

[2] UCSF, Ctr Translat & Policy Res Personalized Med, San Francisco, CA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2011年 / 9卷 / 11期

关键词：

Colon cancer; colorectal cancer; biomarker; KRAS; BRAF; microsatellite instability; mismatch repair; REVISED BETHESDA GUIDELINES; DEFECTIVE MISMATCH REPAIR; CIRCULATING TUMOR-CELLS; MICROSATELLITE-INSTABILITY; ADJUVANT CHEMOTHERAPY; COLON-CANCER; LYNCH-SYNDROME; PREDICTIVE BIOMARKERS; MOLECULAR PREDICTORS; THYMIDYLATE SYNTHASE;

D O I：

10.6004/jnccn.2011.0105

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Biomarkers reflective of the molecular and genetic heterogeneity in colorectal cancers now guide certain aspects of clinical management and offer great potential for enrichment, stratification, and identification of novel therapeutic targets in drug development. Using case-based examples, this article reviews biomarkers that have an established role in the clinical management of colorectal cancer: mismatch repair protein testing and KRAS and BRAF mutational analysis. A selection of biomarkers undergoing validation for future clinical application is presented, and the dynamic and challenging interface between biomarkers in research and clinical practice is discussed. (JNCCN 2011;9:1293-1303)

引用

页码：1293 / 1302

页数：10

共 50 条

[1] Biomarker-based selection of therapy for colorectal cancer
Ross, Jeffrey S.
BIOMARKERS IN MEDICINE, 2011, 5 (03) : 319 - 332
[2] BIOMOLECULAR PROFILE OF COLORECTAL CANCER - THE ROLE OF TELOMERASE AS A POTENT BIOMARKER
Tsiaoussis, John
Vassilopoulou, Loukia
Nikolouzakis, Taxiarchis
Rakitskii, Valerii N.
Vakonaki, Eleni
Fragkiadaki, Persefoni
Stivaktakis, Polychronis
Tsatsakis, Aristides M.
FARMACIA, 2017, 65 (05) : 643 - 659
[3] Pathological diagnosis for individualized therapy of colorectal cancer
Kirchner, T.
Jung, A.
PATHOLOGE, 2010, 31 (01): : 16 - 21
[4] HSP110 as a Diagnostic but Not a Prognostic Biomarker in Colorectal Cancer With Microsatellite Instability
Tachon, Gaelle
Chong-Si-Tsaon, Arnaud
Lecomte, Thierry
Junca, Audelaure
Frouin, Eric
Miquelestorena-Standley, Elodie
Godet, Julie
Evrard, Camille
Randrian, Violaine
Chautard, Romain
Auriault, Marie-Luce
Moulin, Valerie
Guyetant, Serge
Fromont, Gaelle
Karayan-Tapon, Lucie
Tougeron, David
FRONTIERS IN GENETICS, 2022, 12
[5] The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy
Ha Thi Nguyen
Hong-Quan Duong
ONCOLOGY LETTERS, 2018, 16 (01) : 9 - 18
[6] Promising Colorectal Cancer Biomarkers for Precision Prevention and Therapy
Turano, Mimmo
Delrio, Paolo
Rega, Daniela
Cammarota, Francesca
Polverino, Alessia
Duraturo, Francesca
Izzo, Paola
De Rosa, Marina
CANCERS, 2019, 11 (12)
[7] Predictive model for high-frequency microsatellite instability in colorectal cancer patients over 50years of age
Fujiyoshi, Kenji
Yamaguchi, Tatsuro
Kakuta, Miho
Takahashi, Akemi
Arai, Yoshiko
Yamada, Mina
Yamamoto, Gou
Ohde, Sachiko
Takao, Misato
Horiguchi, Shin-ichiro
Natsume, Soichiro
Kazama, Shinsuke
Nishizawa, Yusuke
Nishimura, Yoji
Akagi, Yoshito
Sakamoto, Hirohiko
Akagi, Kiwamu
CANCER MEDICINE, 2017, 6 (06): : 1255 - 1263
[8] A Review of Translational Research for Targeted Therapy for Metastatic Colorectal Cancer
Ruff, Samantha M.
Pawlik, Timothy M.
CANCERS, 2023, 15 (05)
[9] HER2 as a potential biomarker guiding adjuvant chemotherapy in stage II colorectal cancer
Feng, Yang
Li, Yaqi
Huang, Dan
Cai, Sanjun
Peng, Junjie
EJSO, 2019, 45 (02): : 167 - 173
[10] Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies
Akkad, Jamil
Bochum, Sylvia
Martens, Uwe M.
LANGENBECKS ARCHIVES OF SURGERY, 2015, 400 (02) : 129 - 143

← 1 2 3 4 5 →